Molecular testing

0analytes

6orderable panels

1platform

A single organism's amplification curve crosses the detection threshold at cycle 24.4, which is its Ct value. The assay's limit of detection for this target is cycle 31.5. The difference, 7.1 cycles, is reported as cycles above the limit of detection and corresponds to roughly a hundredfold margin over the faintest detectable signal, which the report summarises as a medium organism load. Synthetic data shown for illustration. — From amplification curve to the line a clinician reads.

Method

qPCR — CORE-ABR molecular panel

Real-time polymerase chain reaction

Organisms are detected and quantified; resistance genes are reported qualitatively as detected or not detected. Reports are generated by CORE-ABR, which applies organism-aware antibiotic ranking incorporating intrinsic biology, detected resistance genes, and site-specific rules.

Reporting

Reported through CORE-ABR

PACT — Pathogen Assessment & Clinical Treatment

Molecular results do not leave this laboratory as a list of organisms and genes. Every specimen on this platform is reported through CORE-ABR, which quantifies each organism detected, maps every detected resistance gene to the agents it removes, encodes intrinsic resistance per organism, and marks agents that do not apply to the specimen site rather than listing them. Targets tested and not detected are reported alongside those that were.

Assessment and therapy Organisms quantified, with scenario-based first-line and alternative agents and a stated duration. Written for primary care, nurse practitioners and urgent care
Full antibiogram Every agent graded for activity, each grade carrying its basis — intrinsic biology, a detected gene, or the specimen site. Written for wound care, infectious disease and podiatry
Molecular detail Every target on the panel, including those tested and not detected, under the laboratory's CLIA number and Director. Written to be the record

The antibiogram is derived from the organisms and resistance genes detected, the intrinsic biology of those organisms, and the specimen site. It is not phenotypic susceptibility testing: a detected gene predicts resistance, but the absence of a detected gene does not establish susceptibility. Full method limitations.

Orderable panels 6

Genotyping — MTHFR + COMT components bill separately
A genotype describes enzyme capacity, not a clinical state. It is fixed at birth, identical on every specimen, and does not change with treatment, diet or time — so it says something about the machinery, not about what the machinery is currently doing. Both variants are common in the general population, and carrying one is not itself a finding. Where the question is what methylation is actually doing, the measurements answer it: homocysteine, folate and vitamin B-12, all of which Clinicore runs. A genotype can inform how those results are read; it does not substitute for them.
Wound panel components bill separately
Molecular detection in wound specimens recovers colonizing organisms as well as pathogens. Reports characterize colonizer likelihood. Molecular detection does not replace phenotypic susceptibility testing.
STI / STD profile components bill separately
Basic UTI profile components bill separately
Molecular detection in urine specimens recovers colonizing organisms as well as pathogens.
Complete Care UTI / STI components bill separately
Antibiotic resistance profile components bill separately
Detection of a resistance gene predicts resistance. Absence of a detected gene does NOT establish susceptibility — resistance arises through mechanisms outside the target set, including efflux and porin changes. Molecular detection does not replace phenotypic susceptibility testing.

Every test in this line

The catalog lists all 0 analytes with method, specimen, codes, and reportable range or cutoff.

Browse the molecular testing catalog